HCPCS Code Descriptor:
Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
Route of Administration:
HERZUMA is an Oncology Biosimilar drug manufactured by Teva and administered via the Intravenous route of administration. The Q Code: Q5113 is aligned to the drug HERZUMA.
Herzuma (trastuzumab) is used to treat specific types of breast and stomach cancers by targeting the HER2 protein in cancer cells. Herzuma can be used in combination with other cancer medications. This medication is manufactured by Cephalon and is biosimilar to the medication Herceptin (J9356). Herzuma has been aligned to the Q Code Q5113 since July 2019. Patient assistance programs for this medication can be found through Truxima.